Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. 2002

Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain.

The aim of this work was to study the mechanism of free radical formation in type 1 diabetes and its possible prevention. We have found oxidation of blood glutathione and an increase in plasma lipoperoxide levels in both human type 1 diabetes and experimental diabetes. Peroxide production by mitochondria does not increase in diabetes. On the contrary, the activity of xanthine oxidase, a superoxide-generating enzyme, increases in liver and plasma of diabetic animals. The increase in plasma xanthine oxidase activity may be explained by the increase in the hepatic release of this enzyme, which is not due to nonspecific membrane damage: release of other hepatic enzymes, such as the amino transferases, does not increase in diabetes. Superoxide formation by aortic rings of rabbits increases significantly in diabetes. This is completely inhibited by allopurinol, an inhibitor of xanthine oxidase. Heparin, which releases xanthine oxidase from the vessel wall, also decreases superoxide formation by aortic rings of diabetic animals. Treatment with allopurinol decreases oxidative stress in type 1 diabetic patients: hemoglobin glycation, glutathione oxidation, and the increase in lipid peroxidation are prevented. These results may have clinical significance in the prevention of late-onset vascular complications of diabetes.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008929 Mitochondria, Heart The mitochondria of the myocardium. Heart Mitochondria,Myocardial Mitochondria,Mitochondrion, Heart,Heart Mitochondrion,Mitochondria, Myocardial
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
June 2006, Biochemical pharmacology,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
January 1991, Agents and actions,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
September 1991, Journal of biochemistry,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
January 1966, Texas medicine,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
September 1987, The American journal of physiology,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
July 1995, Journal of the National Medical Association,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
June 2002, Free radical research,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
December 2009, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
June 1989, The Journal of biological chemistry,
Marí-Carmen Desco, and Miguel Asensi, and Rafael Márquez, and José Martínez-Valls, and Máximo Vento, and Federico V Pallardó, and Juan Sastre, and José Viña
November 1993, Journal of chemical ecology,
Copied contents to your clipboard!